AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01391013
Drug: 2 nucleoside reverse transcriptase inhibitors (NRTIs)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 NRTIs will be administered as per the package inserts.
Trial: NCT00070954
Drug: ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EgB 761
Trial: NCT02546492
Drug: Acthar gel
RxNorm normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of the study drug in addition to the current maintenance immunosuppressive agents
Trial: NCT00477412
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02265718
Drug: Ritalin
RxNorm normalized name: Ritalin
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
Trial: NCT03250182
Drug: PT010
RxNorm normalized name: Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
Trial: NCT00629811
Drug: Avotermin (Juvista)
RxNorm normalized name: avotermin
DrugBank: Avotermin (DB11955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~* Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~* Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds.
Trial: NCT00104624
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00477412
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00477412
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT00477412
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03924245
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT03924245
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by mouth
Trial: NCT02248454
Drug: Lispro
RxNorm normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Increasing insulin doses
Trial: NCT02769910
Drug: Capsaicin 24 Hours
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dermal patches for transdermal application of Capsaicin, applied for 24 hours
Trial: NCT02769910
Drug: Capsaicin 1 Hour
RxNorm normalized name: capsaicin 1 MG/ML
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dermal patches for transdermal application of Capsaicin, applied for 1 hour
Trial: NCT02014558
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
Trial: NCT02014558
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.
Trial: NCT01934010
Drug: AM-101
RxNorm normalized name: CAM-101
DrugBank: CAM-101 (DB18414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM-101 gel for intratympanic injection
Trial: NCT02055378
Drug: Atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical 0.125% atropine eye drops
Trial: NCT01620814
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01620814
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02014558
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.
Trial: NCT02014558
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
Trial: NCT03861455
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
Trial: NCT01268761
Drug: GnRH antagonist (Cetrorelix)
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: •GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
Trial: NCT03071822
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PIGLETs
Trial: NCT03071822
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PIGLETs
Trial: NCT03071822
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PIGLETs
Trial: NCT03071822
Drug: L-asparaginase
RxNorm normalized name: L-asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIGLETs
Trial: NCT03071822
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PIGLETs
Trial: NCT03071822
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PIGLETs
Trial: NCT00760318
Drug: Keppra
RxNorm normalized name: Keppra
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
Trial: NCT00414518
Drug: Tenofovir disoproxil fumarate/Emtricitabine
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
Trial: NCT00050726
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00414518
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
Trial: NCT02673151
Drug: 68Ga-PSMA-11
RxNorm normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
Trial: NCT01907802
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00261313
Drug: Neulasta
RxNorm normalized name: Neulasta
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
Trial: NCT00261313
Drug: Aranesp
RxNorm normalized name: Aranesp
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If Hb drops below 110, 300mcg Aranesp will be administered.
Trial: NCT02977533
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT02540070
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02540070
Drug: morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02540070
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02540070
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00868127
Drug: Lapaquistat acetate
RxNorm normalized name: Lapaquistat
DrugBank: Lapaquistat (DB16215)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks.
Trial: NCT00868127
Drug: Lapaquistat acetate and additional lipid-lowering therapy
RxNorm normalized name: guggul lipids
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks.
Trial: NCT03736161
Drug: Group A- Tofacitinib
RxNorm normalized name: meningococcal group A polysaccharide
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
Trial: NCT01765192
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast was supplied in tablets.
Trial: NCT01765192
Drug: Roflumilast placebo
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast placebo was supplied in tablets.
Trial: NCT01765192
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast was supplied in tablets.
Trial: NCT01322048
Drug: IV Propranolol and Per Tube Clonidine
RxNorm normalized name: Clonidine
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
Trial: NCT04357808
Drug: Sarilumab
RxNorm normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose treatment with sarilumab 2 x 200 mg subcutaneously
Trial: NCT00136045
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00217568
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00217568
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03623568
Drug: glecaprevir/pibrentasvir tablets
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 weeks of treatment with Mavyret
Trial: NCT03781505
Drug: Paracetamol +caudal ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol + Ropivacaine
Trial: NCT04054375
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
Trial: NCT00243711
Drug: Carboxymethylcellulose sodium and Glycerin
RxNorm normalized name: carboxymethylcellulose / glycerin
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02794519
Drug: Sirukumab
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
Trial: NCT03245398
Drug: Treatment with one of the two regimens of mebendazole
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once in the morning and once in the evening for 3 consecutive days
Trial: NCT00952991
Drug: LAF237 = vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01679795
Drug: Tibolone
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02466438
Drug: Piperacillin-tazobactam
RxNorm normalized name: piperacillin-tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~  * Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~ * Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~* Acute Kidney injury : Dosing as prescribed by treating physician
Trial: NCT04393051
Drug: Baricitinib Oral Tablet
RxNorm normalized name: baricitinib Oral Tablet
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib will be administered by oral route at different dosages according to age and kidney function. The drug will be administered for 14 days, unless occurrence of discontinuation criteria.
Trial: NCT02933372
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
Trial: NCT02638168
Drug: Immediate Release Methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
Trial: NCT00475904
Drug: EpiCept-NP-1 Cream
RxNorm normalized name: Ceramide Np
DrugBank: Ceramide NP (DB14111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
Trial: NCT00475904
Drug: Gabapentin Capsules
RxNorm normalized name: Gabapentin Capsules
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1800mg/day capsules for 4 weeks
Trial: NCT00774800
Drug: Humalog
RxNorm normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00774800
Drug: Humulin-R
RxNorm normalized name: INSULIN REG HUMULIN-R 100 U/ML CARTRIDGE,1.5ML
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00774800
Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
RxNorm normalized name: PEGylated recombinant human hyaluronidase PH20
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03914755
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered via oral tablet
Trial: NCT00696982
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sitagliptin 100 mg once daily for 3 months
Trial: NCT04269356
Drug: BMS-986256
RxNorm normalized name: BMS-986256
DrugBank: Afimetoran (DB16580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04269356
Drug: Milk of magnesia
RxNorm normalized name: MILK OF MAGNESIA
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT02663830
Drug: Sildenafil & clomiphene citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
Trial: NCT00696982
Drug: glibenclamide
RxNorm normalized name: Glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
Trial: NCT03330457
Drug: Betrixaban 80 mg PO QD
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fXa inhibitor
Trial: NCT00142051
Drug: oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxygen fi02 21% (room air)
Trial: NCT01708122
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% intranasal spray
Trial: NCT00719563
Drug: American ginseng
RxNorm normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00420017
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone continuous infusion x 4 days
Trial: NCT00479856
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Small molecule tyrosine kinase inhibitor
Trial: NCT00479856
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT00479856
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy
Trial: NCT02251938
Drug: DE-109 440 μg
RxNorm normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium Dose
Trial: NCT01178099
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral, daily for 12 days
Trial: NCT05652712
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
Trial: NCT02205528
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
Trial: NCT02715167
Drug: Budesonide novolizer
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00470210
Drug: Ribavirin (Copegus®) 1600 mg/day
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (Copegus®) 1600 mg/day
Trial: NCT00470210
Drug: Epoetin β (450 UI/kg/week)
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin β (450 UI/kg/week)
Trial: NCT03354572
Drug: Acetyl cysteine
RxNorm normalized name: Acetyl cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetyl cysteine 150 mg/kg prior to surgery
Trial: NCT00017628
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00017628
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no